pN status predicts outcomes in surgically treated pT1–pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study

2018 ◽  
Vol 275 (11) ◽  
pp. 2787-2795 ◽  
Author(s):  
Xu Qian ◽  
Branko Sinikovic ◽  
Frank Schreiber ◽  
Sebastian Ochsenreither ◽  
Konrad Klinghammer ◽  
...  
2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 336-336
Author(s):  
Christian Maino Vieytes ◽  
Alison Mondul ◽  
Katie Zarins ◽  
Gregory Wolf ◽  
Laura Rozek ◽  
...  

Abstract Objectives Use of diet quality indices has become increasingly common. However, there are no studies, to date, that have examined the relationship of a priori indices with prognostic outcomes in the head and neck squamous cell carcinoma (HNSCC) population. The purpose of this analysis was to examine associations between diet quality in the first two years after diagnosis and mortality in a sample of HNSCC patients. Methods This was a secondary analysis of 396 newly diagnosed HNSCC patients recruited from the University of Michigan Head and Neck Specialized Programs of Research Excellence longitudinal cohort study. Participants completed food frequency questionnaires (FFQs) and health surveys at the time of diagnosis, 1-year post-diagnosis (n = 341), and 2-years post-diagnosis (n = 217). Cox Proportional Hazards models assessed associations between diet quality index score (categorized as quintiles and modeled as a time-varying covariate), all-cause-, and cancer-specific mortality. The indices chosen for examination included the Alternative Mediterranean Diet Index (aMED), Alternate Healthy Eating Index-2010 (AHEI-2010), Dietary Approaches to Stop Hypertension (DASH), and a ketogenic diet index. All models adjusted for age, sex, BMI, HPV-status, tumor site, stage, education, smoking, drinking, and total calorie intake (modeled as time-varying). Results There were 105 total deaths and 67 cancer-related deaths, during a median follow-up time of 3 years. Higher aMED and AHEI-2010 scores were significantly inversely associated with all-cause (HRaMED 0.33, 95% CI: 0.18–0.59, ptrend < 0.0001; HRaHEI 0.34, 95% CI: 0.20–0.58, ptrend < 0.001) and cancer-related mortality (HRaMED 0.28, 95% CI: 0.13–0.59, ptrend = 0.001; HRaHEI 0.35, 95% CI: 0.18–0.71, ptrend < 0.0001). There were no significant associations found with the DASH index. The ketogenic diet index showed an attenuated significant inverse association for the fifth quintile, but there was a lack of linear trend. Conclusions Developing and testing interventions that follow food and quantity guidelines emphasized by the aMED and AHEI-2010 diet quality indices among HNSCC survivors, is warranted. Funding Sources NIH/NCI and a USDA/NIFA Hatch Project.


Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1413 ◽  
Author(s):  
Ifigenia Vasiliadou ◽  
Omar Breik ◽  
Holly Baker ◽  
Isla Leslie ◽  
Van Ren Sim ◽  
...  

Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based chemotherapy. This study evaluates real-world safety and treatment outcomes of non-trial nivolumab use. A retrospective multicenter cohort study of patients with recurrent/metastatic HNSCC treated with nivolumab between January 2017 and March 2020 was performed. Overall, 123 patients were included. The median age was 64 years, the majority of patients were male (80.5%) and had a smoking history (69.9%). Primary outcomes included overall response rate (ORR) of 19.3%, median progression-free survival (PFS) of 3.9 months, 1-year PFS rate of 16.8%, a median overall survival (OS) of 6.5 months and 1-year OS rate of 28.6%. These results are comparable to the CHECKMATE-141 study. Of 27 patients who had PD-L1 status tested, positive PD-L1 status did not significantly affect PFS (p = 0.86) or OS (p = 0.84). Nivolumab was well tolerated with only 15.1% experiencing immune-related toxicities (IRT) and only 6.7% of patients stopping due to toxicity. The occurrence of IRT appeared to significantly affect PFS (p = 0.01) but not OS (p = 0.07). Nivolumab in recurrent/metastatic HNSCC is well tolerated and may be more efficacious in patients who develop IRT.


2019 ◽  
Vol 58 (10) ◽  
pp. 1509-1513 ◽  
Author(s):  
Louise Hill-Madsen ◽  
Claus A. Kristensen ◽  
Elo Andersen ◽  
Jørgen Johansen ◽  
Lisbeth J. Andersen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document